<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147182</url>
  </required_header>
  <id_info>
    <org_study_id>0116-17-KMC</org_study_id>
    <nct_id>NCT04147182</nct_id>
  </id_info>
  <brief_title>Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection</brief_title>
  <official_title>Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dan Leibovici</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertonic saline at the concentration of 3% (hypersel) has been injected for years into
      echinococcal cysts to kill live scolices, and is also known to kill suspended cells by means
      of a steep osmotic gradient and the investigators postulate that perioperative intravesical
      instillation of hypersel for patients with low grade bladder cancer is safe and may be active
      against shedded and suspended tumor cells and thus may decrease recurrence risk.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2018</start_date>
  <completion_date type="Anticipated">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">July 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by Common Terminology Criteriafor Adverse Events of Renal and urinary disorders (CTCAE)Version 5.0,2017, Satisfaction assessed by Clavien-Dindo.</measure>
    <time_frame>12 month</time_frame>
    <description>The investigators monitored the Sodium levels in the blood after the administration of the Hypertonic Saline and documented and measure side effects by Clavien-Dindo scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>TCC</condition>
  <arm_group>
    <arm_group_label>Patient with low grade TCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of 18 years or older able to sign informed consent
A previous diagnosis of low grade bladder cancer
A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography) showing normal upper urinary tract in the 12 months prior to inclusion
Serum creatinine levels ≤ 2.0 mg/dl
Serum sodium levels &lt;146 mg/ml
Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months
Patient is candidate for TURBT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline 3%</intervention_name>
    <description>3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.</description>
    <arm_group_label>Patient with low grade TCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of 18 years or older able to sign informed consent

          2. A previous diagnosis of low grade bladder cancer

          3. A pyelographic imaging examination (CTU, MRU, IVP, antegrade/retrograde pyelography)
             showing normal upper urinary tract in the 12 months prior to inclusion

          4. Serum creatinine levels ≤ 2.0 mg/dl

          5. Serum sodium levels &lt;146 mg/ml

          6. Current bladder tumor diagnosed by endoscopy or imaging in the last 3 months

          7. Patient is candidate for TURBT

        Exclusion Criteria:

          1. Previous history of high grade bladder cancer including carcinoma in situ

          2. Presence of upper urinary tract tumor on imaging

          3. Renal failure with serum creatinine &gt;2.0 mg/dl prior to inclusion

          4. Hypernatremia &gt;146 mg/dl prior to inclusion

          5. Contra-indication to undergo TURBT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaplan MC</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Dan Leibovici</investigator_full_name>
    <investigator_title>Professor Dan Leibovici- Head of the Urology department of Kaplan MC</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

